secwatch.observer — SEC 8-K summary
======================================

Issuer:     HeartSciences Inc. (HSCS)
CIK:        0001468492
Form:       8-K
Filed at:   2023-07-19T23:59:59+00:00
Accession:  0000950170-23-033460
Event type: other_material
Sentiment:  neutral
Materiality: 0.50
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

HeartSciences reports FY2023 progress; MyoVista pivotal study enrollment complete
--------------------------------------------------------------------------------

- Completed patient enrollment for MyoVista wavECG pivotal study; FDA submission on track for later 2023.
- Expanded IP portfolio to 40 granted patents, including US, Korean, and Israeli patents for AI ECG.
- Entered multi-year AI ECG algorithm development collaboration with Rutgers University health system.
- Cash and cash equivalents $1.7M as of April 30, 2023; no revenue (development-stage company).
- AMA issued new Category III reimbursement codes for AI ECG risk assessment, validating market.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1468492/000095017023033460/0000950170-23-033460-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1468492/000095017023033460/hscs-20230719.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-033460

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer